13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment
Patient Outcome Assessment
About this trial
This is an interventional treatment trial for Patient Outcome Assessment
Eligibility Criteria
Inclusion Criteria: Able to understand and provide signed informed consent Willing to receive 13C-pyruvate DNP MRS and return for post-treatment evaluation for the scheduled follow up imaging about 1 week after initiation of chemotherapy. Willing to receive therapy and follow-up as suggested by the tumor board and combined conference meeting in our institution Presence of enlarged neck lymph nodes and/or spleen to serve as localized target for 3C-pyruvate DNP MRS The exclusion criteria include: Contraindicated to MRI study: such as cardiac pacemaker, cochlear implantation, metallic object within eyeball Patients that refuse to, or has poor ability of understanding and comply study conditions, such as severe dementia or difficulty in mobilit Exclusion Criteria: Contraindicated to MRI study: such as cardiac pacemaker, cochlear implantation, metallic object within eyeball Patients that refuse to, or has poor ability of understanding and comply study conditions, such as severe dementia or difficulty in mobilit
Sites / Locations
Arms of the Study
Arm 1
Other
Patients having 13C Pyruvate DNP for lymphoma early treatment response evaluate
In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.